Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYP-1901 (vorolanib)
- Development stage
- Phase 3
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
**EYP-1901** is an investigational, bioerodible sustained-release intravitreal insert containing the small-molecule tyrosine kinase inhibitor vorolanib. It uses EyePoint's Durasert E delivery matrix to provide local, near-zero-order release after a standard intravitreal injection. Vorolanib inhibits vascular endothelial growth factor receptor and platelet-derived growth factor receptor signaling, and preclinical work also supports inhibition of Janus kinase 1 mediated interleukin-6 inflammatory signaling. The product is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema; it remains unapproved. ([eyepointpharma.com](https://eyepointpharma.com/wp-content/uploads/2024/09/Clinical-Reprint-Phase-I-DAVIO-Trial-by-Sunil-Patel-MD-091624.pdf))
- Other names
- DURAVYUvorolanib intravitreal insert
02
Targets
PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)FGFR (FGFR family)FLT3 (Fms related receptor tyrosine kinase 3)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)TYK2 (Tyrosine kinase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on EYP-1901 (vorolanib).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYP-1901 (vorolanib).